"Part of the reason for Genmab’s success is the valuable resources we have access to in Denmark. We have been able to find very highly skilled and experienced professionals who enable us to carry our programs forward in a streamlined fashion. We have also found Denmark to be a prime location in that it provides easy access to clinical sites and capital in other Scandinavian and European countries. Making our start as a Danish company has given us a significant advantage in the competitive field of biotechnology."
- Lisa N. Drakeman, Ph.D., CEO, Genmab A/S
Reasons for choosing Denmark:
- Unique combination of cost and quality
- Access to an excellent research community on all levels from basic research through the clinical phases
- Very strong clinical trials environment with easy access to qualified medical professionals
- A health care system with ample capacity to meet the clinical needs of the biotech industry
- Denmark’s competitiveness as one of the top two cancer centres in Europe and Medicon Valley’s status in the absolute world elite for research in inflammatory conditions
- The support of the local investment community in terms of assembling the right working team and professional network for Genmab
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products – therapeutical areas where Denmark and Medicon Valley are strongly positioned. In addition, Genmab is involved in multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen.
Genmab employs approx. 200 people at its offices in Copenhagen, Utrecht and Princeton. The company is publicly traded on the Copenhagen Stock Exchange with Princeton based GenPharm International, Inc. as the largest stockholder with 25% of the shares.